Monograph
A07AA06 - Paromomycin |
Propably not porphyrinogenic |
PNP |
Rationale
The classification PNP is only valid for oral administration of Paromomycin. Paromomycin when given orally is poorly absorbed from the gastrointestinal tract and most of the dose is eliminated unchanged in the faeces. The absorbed amount of Paromomycin is excreted unchanged in the urine by glomerular filtration. No data available for CYP metabolism. There is no clinical experience of Paromomycin used by porfyria patients.
Chemical description
Paromomycin sulfate is an aminoglycoside antibiotic. The aminoglycosides are polycationic compounds that contain an
aminocyclitol, usually 2-deoxystreptamine, or streptidine in streptomycin and related compounds, with cyclic amino-sugars attached by glycosidic
linkages.
Therapeutic characteristics
Paromomycin is an aminoglycoside antibiotic that has been given orally in
the treatment of intestinal protozoal infections, including amoebiasis,
cryptosporidiosis, and giardiasis. It has also been tried parenterally for
visceral, and topically for cutaneous, leishmaniasis.
Hepatic exposure
Insignificant by oral administration.
Metabolism and pharmacokinetics
Paromomycin when given orally is poorly absorbed from the gastrointestinal tract and most of
the dose is eliminated unchanged in the faeces. The absorbed dose is excreted unchanged
in the urine by glomerular filtration. Aminoglycosides are generally well distributed in the body after parenteral dosage although penetration into the CSF is poor.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Paromomycin. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P.Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.
Davidson RN, den Boer M, Ritmeijer K. |
|
| 2. | Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. N Engl J Med. 2007 Jun 21;356(25):2571-81. |
17582067 |
| 3. | A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.
Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, Olliaro P. |
11127250 |
| * | Drug reference publications | |
| 4. | Martindale
|
|
| 5. | Micromedex
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Belgium
United Kingdom
Norway
Luxembourg© NAPOS 2024